Psychiatric Times
JUNE 25, 2025
SHOW MORE Discover the innovative Borderline Personality Disorder Inventory (BPD-I™), a psychodynamically-informed tool for assessing BPD symptoms effectively. Наталья Добровольска/AdobeStock Borderline personality disorder (BPD) remains one of the most commonly misunderstood and challenging diagnoses in mental health.
Mad in America
APRIL 22, 2025
W hen asked about her behavior during a psychiatric assessment for personality disorders, one patient’s response included this description: It was completely crazy. In the medical psychiatry, psychiatric diagnoses are often presented as neutral objects. I’m not quite that bad anymore.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
AUGUST 1, 2025
children, highlighting its significant prevalence and rising diagnosis rates. children, highlighting its significant prevalence and rising diagnosis rates. children, highlighting its significant prevalence and rising diagnosis rates.
Psychiatric Times
JUNE 12, 2025
2 Realizing that, modern medical educators often morph traditional Socratic questioning into the embedding of “audience response questions” (ARS) within formal presentations. Figure 1 presents a modified version of this conceptualization highlighting the role of the educator as facilitator.
Psychiatric Times
JULY 14, 2025
Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolar disorder. This gap can lead to misdirected treatments, worsening symptoms, and life altering consequences, but the delay is partly due to the disorder’s complex and often difficult to quantify presentation.
Psychiatric Times
JULY 7, 2025
Novel PDE10A Inhibitor for Acute Schizophrenia Exacerbation Presented at APA Annual Meeting CPL’36, a PDE10A inhibitor, showed significant improvements in PANSS scores in a double-blind, randomized, placebo controlled, parallel group phase 2 study for acute schizophrenia exacerbation. Those who received the 40 mg dose demonstrated a 16.4
Psychiatric Times
JUNE 13, 2025
Curiously, anticholinergic medications, including benztropine, diphenhydramine, and trihexyphenidyl, are commonly used to treat all antipsychotic-induced movement disorders despite the fact that they make TD worse and have no benefit for akathisia. Ms Robbins presents to your office for a follow-up visit.
Expert insights. Personalized for you.
Let's personalize your content